Our mission and strategy
PREDICTOM will identify scalable biosignatures for early and accurate diagnosis of Alzheimer’s disease and personalized preventive interventions.
A combination of computerized, digital, fluid and neuroimaging biomarkers can help to identify individual risk factors, enabling the adoption of feasible risk-deduction intervention to the right person, at the right disease stage to ensure maximum effect.
With this mission, we aim to provide healthcare practices cost-effective biomarker collection at home or in primary care, and an open AI platform to analyze biomarker data. The PREDICTOM platform will identify recruited participants at high risk of developing dementia and to direct them to personalized intervention to prevent further cognitive decline and development of dementia. At the end of project, we will produce guidelines for how cost-effective biomarkers can be implemented in health care worldwide.
In short, we will build an advanced screening platform available for all citizens. The citizens can, in turn, receive evidence-based lifestyle advice to regress the development of Alzheimer’s disease.
improve access to the existing and discover new biomarkers for risk assessment.
increase awareness and enable the implementation of disease modifying strategies.
change current healthcare practices by developing an effective system to prioritize patients (triage) with higher risk of developing Alzheimer’s disease.
Who can benefit from PREDICTOM results?
Our digital platform will store each participant’s relevant data, and provide tools for risk assessment, early diagnosis, and prognosis. A wide range of users will benefit from PREDICTOM results.
Citizens
People who have not yet been diagnosed with Alzheimers disease but feel worried about their health, will be able to perform an online self assessment of their cognitive abilities as well as their lifestyle dependent dementia risk factors in agreement to the WHO guidelines.
General practitioners (GPs)
GPs will be able to use the PREDICTOM platform to further assess the patient’s risk of developing dementia based on our evidenced-based biomarkers.
Specialist healthcare professionals
Healthcare specialists will be able to use the PREDICTOM platform as a central hub for all patient associated data.
Researchers
Academics will be able to work with the data and the algorithms stored on the platform after completion of PREDICTOM and in strict agreement to the legal constraints.
What is Alzheimer's disease?
Alzheimer’s disease is the most common cause of dementia, thought to account for over 50% of cases. Like most other types of dementia, Alzheimer’s disease is progressive, with symptoms worsening over time.